
|Videos|August 18, 2017
Dr. Modest Discusses the German AIO KRK0110 Study in CRC
Author(s)Dominik P. Modest, MD
Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.
Advertisement
Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).
AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.
This sequence study aims to answer the question of de-escalation in this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































